The Role of Beta Cell Recovery in Type 2 Diabetes Remission.

Mara Suleiman, Lorella Marselli, Miriam Cnop, Decio L Eizirik, Carmela De Luca, Francesca R Femia, Marta Tesi, Silvia Del Guerra, Piero Marchetti

Journal: International journal of molecular sciences 2022;23(13):7435

PMID: 35806437

Abstract

Type 2 diabetes (T2D) has been considered a relentlessly worsening disease, due to the progressive deterioration of the pancreatic beta cell functional mass. Recent evidence indicates, however, that remission of T2D may occur in variable proportions of patients after specific treatments that are associated with recovery of beta cell function. Here we review the available information on the recovery of beta cells in (a) non-diabetic individuals previously exposed to metabolic stress; (b) T2D patients following low-calorie diets, pharmacological therapies or bariatric surgery; (c) human islets isolated from non-diabetic organ donors that recover from "lipo-glucotoxic" conditions; and (d) human islets isolated from T2D organ donors and exposed to specific treatments. The improvement of insulin secretion reported by these studies and the associated molecular traits unveil the possibility to promote T2D remission by directly targeting pancreatic beta cells.

Address: Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.; ULB Center for Diabetes Research, Université Libre de Bruxelles, 1050 Brussels, Belgium.; Division of Endocrinology, ULB Erasmus Hospital, Université Libre de Bruxelles, 1050 Brussels, Belgium.; Departmental Section of Endocrinology and Metabolism of Transplantation, AOUP Cisanello Hospital, 56124 Pisa, Italy.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.